Navigating the Future of Clinical Research: February 2025 GLSA Lunch n Learn Key Takeaways
Event: February 2025
AI in clinical research is rapidly shaping how studies are designed, managed, and regulated. The February 2025 GLSA Lunch n’ Learn brought together industry leaders to discuss artificial intelligence, regulatory compliance, data privacy, and collaboration as key drivers of the future of clinical trials.
AI in Clinical Research and the Power of Networking
To begin, Denise McNerney reflected on recent clinical research conferences and the energy they bring to professional networking. She emphasized how in-person and virtual connections continue to strengthen the GLSA Network.
Jorge Franceschi echoed this sentiment, sharing how meaningful industry connections often lead to collaboration, innovation, and long-term partnerships. Together, these interactions reinforce GLSA’s mission of connecting sponsors, solution providers, and research professionals.
GLSA Network Partners and Specialized Expertise
Next, GLSA highlighted several Network Partners who bring specialized expertise across clinical trial operations:
-
Chris Matheus discussed the growing role of AI in clinical trials and its potential to transform operations.
-
Sourav Neil Banerjee focused on regulatory compliance and AI-driven risk assessment.
-
Peter Payne shared insights on operational efficiency and research oversight.
-
Marlyn Brookins and Tina Karunaratne highlighted the importance of community engagement and streamlined project execution.
AI in Clinical Research: Innovation, Compliance, and Risk
As AI in clinical research continues to expand, organizations must balance innovation with regulatory expectations and ethical responsibilities. A central theme of the Lunch n’ Learn was the expanding role of AI in clinical trials. In particular, the discussion explored how AI is being used in patient recruitment, data management, and operational efficiency.
Sourav “Neil” Banerjee emphasized the importance of aligning AI use with regulatory expectations, referencing the FDA’s draft guidance on structured approaches to AI in clinical research. Building on this, Charles Schmidt addressed the complexity of patient data regulations and the ethical considerations tied to AI-driven recruitment.
Data Privacy and Ethical Considerations
As the conversation progressed, data privacy emerged as a critical concern. Speakers stressed the importance of transparency and ethical data use, especially in global trials.
Denise McNerney highlighted how a strong global network can help organizations navigate regulatory differences across regions. Sara Tylosky added perspective on data sovereignty challenges in Latin America, underscoring the need for region-specific compliance strategies.
Balancing AI in Clinical Research with Human Oversight
To close the session, participants agreed that while AI can significantly enhance productivity in clinical trials, human oversight remains essential. Ethical decision-making, regulatory compliance, and patient trust all depend on maintaining a balance between automation and expert judgment.
Attendees expressed appreciation for the collaborative discussion and the opportunity to continue conversations within the GLSA community.
Key Takeaways for Clinical Research Professionals:
-
Networking remains essential for building partnerships and advancing research
-
AI in clinical trials continues to evolve, with increased focus on compliance and patient safety
-
Data privacy and ethics must remain a top priority in global research
-
Regulatory alignment and risk assessment are critical for successful AI integration
-
Collaboration across the industry drives innovation and operational efficiency
Looking Ahead
Looking ahead, AI in clinical research will remain a critical focus as sponsors and research teams adapt to evolving technologies and compliance requirements.
As clinical research continues to evolve, GLSA remains committed to providing thought leadership, fostering partnerships, and providing cost-effective, cutting-edge solutions to advance the industry. Stay connected with GLSA for more insights and upcoming Lunch n’ Learn sessions!
About GLSA
Global Life Sciences Alliance (GLSA) connects biotechs, pharma, CROs, and clinical research sites with the right experts, advisors, and solutions to accelerate development and reduce risk. With a network of more than 200 trusted partners spanning pre-clinical and clinical research, GLSA offers flexible, cost-effective access to specialized expertise and services that support early-stage biotechs, mid-size pharma, and global pharmaceutical companies.
When you need trusted, global resources to accelerate your research, GLSA helps you scale smarter and move you forward with confidence.
To learn how GLSA can support your organization, connect with Denise McNerney or Chris Matheus for a conversation about your goals and challenges.